Studies to be presented on safety and efficacy of SpyGlass System for diagnostic and therapeutic procedures throughout pancreatico-biliary system
NATICK, Mass., May 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that 14 abstracts and additional clinical data analyses involving the SpyGlass(R) Direct Visualization System will be presented at Digestive Disease Week(R) (DDW), which runs from May 30 to June 4 in Chicago.
"The impressive number of presentations on the SpyGlass System underscores the potential of this technology as a vital new tool in endoscopic procedures for diagnosing and treating pancreatic and biliary disease," said Michael P. Phalen, President, Boston Scientific Endoscopy. "Boston Scientific is dedicated to developing technologies and expanding indications that enhance the quality of life for patients, as demonstrated by our new pancreatic indication for the SpyGlass System, as well as the broad range of endoscopic innovations showcased at DDW."
Previously available for use only in the bile and hepatic ducts, Boston Scientific recently received clearance from the Food and Drug Administration to market its SpyScope(R) Access and Delivery Catheter for diagnostic and therapeutic applications during endoscopic procedures in the entire pancreatico-biliary system, including the pancreatic ducts. The SpyScope Catheter is used in conjunction with the SpyGlass Direct Visualization System. The system is intended to guide visualization and accessory devices throughout the pancreatico-biliary system, enabling physicians to diagnose and treat pancreatic cancer or pre-cancerous tissues.
The SpyGlass System is a single-operator system developed to overcome the challenges of traditional cholangioscopy systems and reduce the need for exploratory surgery.
|SOURCE Boston Scientific Corporation|
Copyright©2009 PR Newswire.
All rights reserved